BioSpace

Stability, speed and strategy: Inside Australia’s early‑stage edge

October 29, 2026·21 min
Episode Description from the Publisher

In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJerome Barley, Commercial Director, Avion MedicalRyan Klein, Vice President, Business Development, US and APAC, ResolianDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Podzilla Summary coming soon

Sign up to get notified when the full AI-powered summary is ready.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.

Listen to This Episode

Get summaries like this every morning.

Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.